Skip to main content

Sexual and Gender Minorities

0
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Impact Therapeutics
Impact TherapeuticsChina - Shanghai
1 program
NPOWER365 HIV care interventionN/A1 trial
Active Trials
NCT06315218Not Yet Recruiting350Est. Apr 2028
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
SGM Communication InterventionN/A1 trial
Active Trials
NCT05877391Recruiting80Est. Sep 2027

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
2028
Impact TherapeuticsNPOWER365 HIV care intervention
Colorado TherapeuticsSGM Communication Intervention

Clinical Trials (2)

Total enrollment: 430 patients across 2 trials

NCT06315218Impact TherapeuticsNPOWER365 HIV care intervention

Examining the Health Effects of NPOWER365 Among Black Same Gender Loving Men

Start: Mar 2026Est. completion: Apr 2028350 patients
N/ANot Yet Recruiting
NCT05877391Colorado TherapeuticsSGM Communication Intervention

Intervention to Collect and Utilize Sexual Orientation and Gender Identity (SOGI) Information in Hospice

Start: Mar 2023Est. completion: Sep 202780 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 430 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.